According to her, the total amount is around 45 lakh, but users pointed out that she hasn't included living costs after ...

HXN-1001 is a half-life extended, next generation anti-TL1A antibody with great potential for the treatment of patients with inflammatory bowel disease (IBD) including ulcerative colitis and Crohn’s ...

First-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways with preclinical efficacy and a ...

Global development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the ...

NMC Extends Application Deadline for New PG, SS Courses and Seat Increase for 2026-27 Under Revised PGMSR NormsDue to the recent regulatory changes ...

UH President Renu Khator wants to expand the school's suburban footprint. To do it, she'll need millions from donors or state ...

Rezpegaldesleukin demonstrates statistically significant improvement in mean percent EASI improvement across both moderate and severe atopic dermatitis patients ...

An executive order upended an NIH policy requiring researchers to account for both sexes in preclinical animal studies.

Primary and Key Secondary Endpoints Met 77% of Patients Achieved Highly Statistically Significant Proptosis Response Study Showed Clinically Meaningful Reduction ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 23, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the Company), a global biopharmaceutical company committed to the discovery and ...

Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention ...